Zachary Thomas Herbert, M.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sequence Analysis, RNA | 3 | 2020 | 2039 | 0.820 |
Why?
|
| Gene Library | 3 | 2020 | 1065 | 0.720 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 3666 | 0.680 |
Why?
|
| RNA, Ribosomal | 1 | 2018 | 227 | 0.550 |
Why?
|
| Tuberous Sclerosis | 3 | 2023 | 1039 | 0.330 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2023 | 480 | 0.300 |
Why?
|
| Carboplatin | 2 | 2021 | 789 | 0.270 |
Why?
|
| MicroRNAs | 1 | 2020 | 3792 | 0.230 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2021 | 82 | 0.190 |
Why?
|
| Facial Neoplasms | 1 | 2022 | 126 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2022 | 2160 | 0.180 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2019 | 35 | 0.170 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 4780 | 0.170 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 3944 | 0.170 |
Why?
|
| Histone Demethylases | 2 | 2019 | 328 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2024 | 8621 | 0.160 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2019 | 30 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2022 | 309 | 0.160 |
Why?
|
| Neuroendocrine Cells | 1 | 2019 | 61 | 0.160 |
Why?
|
| Triterpenes | 1 | 2019 | 78 | 0.150 |
Why?
|
| Angiomyolipoma | 1 | 2020 | 189 | 0.150 |
Why?
|
| Telomerase | 1 | 2023 | 750 | 0.150 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2018 | 142 | 0.150 |
Why?
|
| Poly A | 1 | 2018 | 180 | 0.150 |
Why?
|
| Phospholipase D | 1 | 2017 | 71 | 0.140 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 771 | 0.140 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 328 | 0.140 |
Why?
|
| Immunity | 2 | 2022 | 1002 | 0.130 |
Why?
|
| Cell Dedifferentiation | 1 | 2017 | 125 | 0.130 |
Why?
|
| Enteroendocrine Cells | 1 | 2017 | 79 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2023 | 2801 | 0.130 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 314 | 0.130 |
Why?
|
| Autoantigens | 1 | 2020 | 886 | 0.130 |
Why?
|
| Epigenomics | 2 | 2019 | 959 | 0.130 |
Why?
|
| Ovarian Neoplasms | 2 | 2023 | 4904 | 0.130 |
Why?
|
| Anti-Obesity Agents | 1 | 2019 | 241 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 183 | 0.120 |
Why?
|
| Software | 2 | 2020 | 4466 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2019 | 751 | 0.120 |
Why?
|
| Astrocytoma | 1 | 2019 | 773 | 0.120 |
Why?
|
| Prostatic Neoplasms | 3 | 2024 | 11094 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 454 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2015 | 370 | 0.110 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 426 | 0.110 |
Why?
|
| Mice | 17 | 2024 | 81889 | 0.110 |
Why?
|
| Imidazoles | 1 | 2020 | 1168 | 0.110 |
Why?
|
| Interleukin-17 | 1 | 2020 | 923 | 0.110 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 591 | 0.110 |
Why?
|
| Duodenum | 1 | 2017 | 495 | 0.110 |
Why?
|
| Astrocytes | 1 | 2022 | 1351 | 0.110 |
Why?
|
| Histones | 3 | 2019 | 2593 | 0.110 |
Why?
|
| Autoimmunity | 1 | 2021 | 1358 | 0.110 |
Why?
|
| Myeloid Cells | 1 | 2018 | 838 | 0.110 |
Why?
|
| Signal Transduction | 7 | 2021 | 23619 | 0.110 |
Why?
|
| Cytokines | 3 | 2022 | 7438 | 0.110 |
Why?
|
| Workflow | 1 | 2018 | 859 | 0.100 |
Why?
|
| RNA Splicing | 1 | 2017 | 903 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2018 | 1195 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2823 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 1026 | 0.100 |
Why?
|
| Kidney Neoplasms | 2 | 2020 | 4282 | 0.100 |
Why?
|
| Intestine, Small | 1 | 2018 | 1217 | 0.100 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 1363 | 0.100 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2024 | 1882 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 1814 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 4410 | 0.100 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 895 | 0.100 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 659 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3607 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2022 | 3114 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2023 | 2561 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 1646 | 0.090 |
Why?
|
| Cell Differentiation | 4 | 2024 | 11651 | 0.090 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 1838 | 0.090 |
Why?
|
| Leptin | 1 | 2019 | 1596 | 0.090 |
Why?
|
| Mice, Knockout | 6 | 2022 | 14471 | 0.090 |
Why?
|
| Animals | 19 | 2024 | 168930 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2023 | 2355 | 0.090 |
Why?
|
| HEK293 Cells | 4 | 2021 | 4276 | 0.080 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 17088 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 1245 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 2056 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 2254 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3601 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1885 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 4652 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2021 | 12791 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2022 | 3446 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2020 | 3043 | 0.070 |
Why?
|
| Leukemia | 1 | 2016 | 1521 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 9525 | 0.070 |
Why?
|
| Oxygen | 1 | 2019 | 4251 | 0.070 |
Why?
|
| Chromatin | 1 | 2019 | 2977 | 0.070 |
Why?
|
| Lymphoma | 1 | 2016 | 1900 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2023 | 4142 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2021 | 2628 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 3636 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 5194 | 0.060 |
Why?
|
| Genomics | 1 | 2021 | 5923 | 0.060 |
Why?
|
| Humans | 27 | 2024 | 766766 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2019 | 4427 | 0.060 |
Why?
|
| Stem Cells | 1 | 2017 | 3537 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 5795 | 0.060 |
Why?
|
| HIV-1 | 1 | 2021 | 6948 | 0.060 |
Why?
|
| Cell Proliferation | 4 | 2021 | 10445 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 3186 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 13643 | 0.050 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2024 | 148 | 0.050 |
Why?
|
| Inflammation | 2 | 2021 | 10860 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 6104 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 5329 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 20144 | 0.050 |
Why?
|
| Kidney | 1 | 2017 | 7074 | 0.050 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2021 | 72 | 0.050 |
Why?
|
| Cell Lineage | 2 | 2024 | 2572 | 0.050 |
Why?
|
| Base Pair Mismatch | 1 | 2021 | 93 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2023 | 12150 | 0.050 |
Why?
|
| Homeodomain Proteins | 2 | 2023 | 2430 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5444 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2022 | 272 | 0.040 |
Why?
|
| Templates, Genetic | 1 | 2020 | 188 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 2839 | 0.040 |
Why?
|
| Nucleotides | 1 | 2022 | 454 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 502 | 0.040 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2019 | 36 | 0.040 |
Why?
|
| Arginine | 1 | 2022 | 932 | 0.040 |
Why?
|
| Serine | 1 | 2022 | 828 | 0.040 |
Why?
|
| Virus Latency | 1 | 2021 | 359 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2019 | 192 | 0.040 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2019 | 169 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 630 | 0.040 |
Why?
|
| Sphingosine | 1 | 2020 | 306 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 9101 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2020 | 565 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2020 | 336 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2020 | 828 | 0.040 |
Why?
|
| Virus Internalization | 1 | 2021 | 504 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2019 | 299 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2023 | 1089 | 0.030 |
Why?
|
| DNA | 2 | 2021 | 7208 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2024 | 1802 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 18330 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 1142 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2019 | 661 | 0.030 |
Why?
|
| Obesity | 1 | 2019 | 13090 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 1477 | 0.030 |
Why?
|
| Receptor, trkA | 1 | 2017 | 159 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2020 | 812 | 0.030 |
Why?
|
| Genome, Bacterial | 1 | 2021 | 796 | 0.030 |
Why?
|
| Methylation | 1 | 2019 | 1074 | 0.030 |
Why?
|
| Androgens | 1 | 2023 | 1280 | 0.030 |
Why?
|
| Oncogenes | 1 | 2022 | 1231 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 224 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 2221 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2022 | 862 | 0.030 |
Why?
|
| Oligodendroglia | 1 | 2019 | 539 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 1627 | 0.030 |
Why?
|
| Apoptosis | 2 | 2021 | 9513 | 0.030 |
Why?
|
| Benchmarking | 1 | 2021 | 1056 | 0.030 |
Why?
|
| HIV Infections | 1 | 2021 | 17536 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 1411 | 0.030 |
Why?
|
| Histone Code | 1 | 2015 | 160 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2017 | 10100 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2019 | 1244 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 350 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 428 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 230 | 0.030 |
Why?
|
| Mutation | 3 | 2023 | 30213 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 2881 | 0.030 |
Why?
|
| Female | 10 | 2023 | 396520 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 665 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2021 | 1806 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 13485 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 361 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2018 | 2177 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 2142 | 0.030 |
Why?
|
| Cadherins | 1 | 2018 | 902 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 711 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 1144 | 0.030 |
Why?
|
| Virus Replication | 1 | 2021 | 2457 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 1466 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2021 | 2448 | 0.030 |
Why?
|
| Male | 9 | 2024 | 364142 | 0.030 |
Why?
|
| Synapses | 1 | 2022 | 1759 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 1491 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2012 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2018 | 3616 | 0.020 |
Why?
|
| Immune System | 1 | 2017 | 800 | 0.020 |
Why?
|
| Phenotype | 2 | 2023 | 16724 | 0.020 |
Why?
|
| DNA Damage | 1 | 2021 | 2467 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 1609 | 0.020 |
Why?
|
| Cell Communication | 1 | 2018 | 1660 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2020 | 2325 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2018 | 2717 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 21162 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2017 | 1504 | 0.020 |
Why?
|
| Neutrophils | 1 | 2023 | 3782 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2018 | 2931 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 2901 | 0.020 |
Why?
|
| Folic Acid | 1 | 2017 | 1337 | 0.020 |
Why?
|
| Microglia | 1 | 2019 | 1370 | 0.020 |
Why?
|
| Fibrosis | 1 | 2017 | 2077 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2017 | 2201 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 22352 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 1730 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3609 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 1805 | 0.020 |
Why?
|
| Genome, Human | 1 | 2021 | 4443 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4570 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 3425 | 0.020 |
Why?
|
| Cell Movement | 1 | 2020 | 5199 | 0.020 |
Why?
|
| Proteomics | 1 | 2021 | 3914 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2018 | 4032 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 3609 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 2463 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 4619 | 0.020 |
Why?
|
| Base Sequence | 1 | 2018 | 12415 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2018 | 3139 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 6359 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 6850 | 0.020 |
Why?
|
| Prognosis | 2 | 2017 | 29948 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 4891 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2017 | 2101 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1894 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 15563 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 4562 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2547 | 0.020 |
Why?
|
| Macrophages | 1 | 2020 | 5783 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 9547 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 18075 | 0.010 |
Why?
|
| Alleles | 1 | 2015 | 6895 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3113 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 11920 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13640 | 0.010 |
Why?
|
| Neurons | 1 | 2022 | 9515 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 11218 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 10264 | 0.010 |
Why?
|
| Diet | 1 | 2019 | 8088 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 6207 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10384 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 9611 | 0.010 |
Why?
|
| Time Factors | 1 | 2018 | 40149 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11872 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12806 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 16044 | 0.010 |
Why?
|
| Aged | 2 | 2018 | 171343 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 41710 | 0.010 |
Why?
|
| Middle Aged | 2 | 2018 | 223257 | 0.010 |
Why?
|
| Adult | 2 | 2018 | 223307 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 59550 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 81635 | 0.000 |
Why?
|